Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.

Release Date:  April 13, 1998

RFA:  AI-98-008


National Institute of Allergy and Infectious Diseases

Letter of Intent Receipt Date:  June 15, 1998
Application Receipt Date:  October 14, 1998



The Division of Microbiology and Infectious Diseases (DMID) of the National
Institute of Allergy and Infectious Diseases (NIAID) invites applications for the
continuation and/or establishment of high-quality Chronic Fatigue Syndrome
Cooperative Research Centers (CFS CRCs) that provide a multi-disciplinary,
systematic, sustained approach to the study of CFS.  A nucleus of CFS CRC
investigators dedicated to use of standardized methodologies and collaborative
efforts was established in 1991.  The program was renewed in 1995.  Currently,
two CFS CRCs are supported.  This RFA is the second recompetition.  For the first
time, eligibility is being extended to foreign organizations either as projects
within a domestic CFS CRC or as a full Center.


The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2000," a PHS-led national
activity for setting priority areas.  This RFA, Chronic Fatigue Syndrome
Cooperative Research Centers, is related to the priority area of chronic
disabling conditions.  Potential applicants may obtain a copy of "Healthy People
2000" (Full Report:  Stock No. 017-001-00474-0 or Summary Report:  Stock No. 017-
001-00473-1) through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-512-1800).


Research grant applications may be submitted by domestic and foreign for-profit
and non-profit organizations, public and private institutions, such as
universities, colleges, hospitals, laboratories, units of State and local
governments, and eligible agencies of the Federal government.  Racial/ethnic
minority individuals, women, and persons with disabilities are encouraged to
apply as Principal Investigators.


The administrative and funding mechanism to be used to undertake this program
will be the Multiproject Cooperative Agreement (U19), an "assistance" mechanism,
rather than an "acquisition" mechanism.  Under the cooperative agreement, the NIH
purpose is to support and/or stimulate the recipient's activity by involvement
in and otherwise working jointly with the award recipient in a partner role, but
it is not to assume direction, prime responsibility, or a dominant role in  the
activity.  Essential elements of the multiproject cooperative agreement mechanism
also include: (1) a minimum of three interrelated individual research projects
organized around a central theme; (2) collaborative efforts and interaction among
independent projects and their investigators to achieve a common goal; (3) a
single Principal Investigator who will be scientifically and administratively
responsible for the group effort; (4) a single applicant institution that will
be legally and financially responsible for the use and disposition of funds
awarded, although, Projects may be located at different institutions as
subcontracts; and (5) support provided, as necessary, for "Core" resources or
facilities, each of which is expected to be utilized by at least two research
projects in order to facilitate the research effort.  Details of the
responsibilities, relationships and governance of a study funded under a
cooperative agreement are discussed later in this document under the section
"Terms and Conditions of Award."

The total project period for an application submitted in response to this RFA may
not exceed five years.


The estimated total funds (direct and indirect) available for the first year of
support for this RFA will be $1.6 million.  In fiscal year 1999, the NIAID plans
to make approximately two awards related to this RFA.  This level of support is
dependent on the receipt of a sufficient number of applications of high
scientific merit.

Applications may not request budgets in excess of $800,000 in total (direct and
indirect) costs in the first year without prior concurrence of the NIAID
Scientific Coordinator, Dr. Sawyer (see INQUIRIES below).  The usual PHS policies
governing grants administration and management will apply.  Although this program
is provided for in the financial plans of the NIAID, awards pursuant to this RFA
are contingent upon the availability of funds for this purpose.  Funding beyond
the first and subsequent years of the grant will be contingent upon satisfactory
progress during the preceding years and availability of funds.

At this time, the NIAID has not determined whether or how this solicitation will
be continued beyond the present RFA.



Research spanning the last decade has established that CFS is an illness
characterized by a multisystem syndrome.  Although in some cases, CFS may be
triggered by an infection, to date, no known infectious agents have been
established as a specific cause of CFS.  CFS is characterized by months of
debilitating fatigue frequently associated with sore throat, low grade fever,
myalgia, headache, gastrointestinal symptoms and tender lymph nodes.  Several
different scientific disciplines have provided clues as to CSF pathophysiology. 
Cognitive deficits, symptoms of depression and sleep disorders have been reported
and abnormal brain images derived by different techniques have also been
described.  CFS patients are reported to have neuroendocrine response patterns
which differ from those of controls.  A subgroup of patients may suffer from
treatable neurally mediated hypotension; however, conclusive studies are still
in progress.  CFS is diagnosed more frequently in women than in men.  There have
been numerous reports of specific immune abnormalities, but no single impairment
has regularly been associated with the syndrome.

There have been many formidable obstacles to the effective study of this
syndrome, the most serious of which has been the lack of objective diagnostic
criteria.  Recently, there has been progress in the development of instruments
which may differentiate CFS from other neuropsychiatric disorders such as
depression.  For the most part, CFS is still a diagnosis of exclusion resulting
in extensive testing and referrals which often lead to expense and delay in
making the diagnosis, a diagnosis for which management guidelines are the only
remedy physicians can offer to patients.

The CFS-CRCs established in FY 91/92 are the focal point of the NIAID-extramural
CFS effort.  The etiology and pathogenesis of this syndrome are not
straightforward.  Progress in these areas as well as in the areas of developing
effective methods of diagnosis and treatment will require an interdisciplinary
approach.  The goal of the CFS-CRCs is consistent with the desire to foster
interactions among the different relevant medical and basic science disciplines. 
It is hoped that the international component to this renewal will bring new
perspectives and hypotheses to the CFS research arena.

Research Objectives and Scope

The purpose of this RFA is to support clinical centers of research excellence
that use standardized methods for patient enrollment and data collection to
pursue multidisciplinary coordinated projects to study the etiology, natural
history, pathogenesis and treatment of CFS.  Expertise in multiple scientific
disciplines including but not limited to: medicine, immunology, virology,
pathophysiology, neurology, endocrinology and epidemiology may be helpful in
furthering our understanding of CFS.  It is not expected that expertise in all
these areas be available at a single institution.  Input from the NIAID
Scientific Coordinator will facilitate technology transfer, assist in the
identification of expert consultants, collaborators and resources, enhance
communication between awardees and help to ensure that pilot studies funded
through the CFS CRC program will complement and not unnecessarily duplicate
existing or planned research endeavors.


A.  Study Organization

The Cooperative Research Center Program requires cooperation between CRC
Directors and the NIAID Scientific Coordinator to maintain a close collaboration
and communication among the CFS CRCs and the Program Officers across the National
Institutes of Health responsible for the scientific discipline appropriate to the

B.  CFS CRC External Advisory Board

The CFS CRC funds may be used to support activities related to acquiring
scientific advise from experts in the field.  These advisory groups should be
constituted after the grant award has been made and should not be named in the
application.  The NIAID Scientific Coordinator will be a member of each External
Advisory Board.

C.  CFS CRC Annual Meeting

Successful applicants will be expected to participate in annual workshops in
Bethesda, MD.  Participants in the workshops will share CFS research advances and
discuss CFS research needs and opportunities with the CRC Directors and other CRC
principal investigators as well as with other investigators active in CFS
research or working in relevant related areas.  SUPPORT FOR TRAVEL TO THE

D.  Clinical Trials

A Data Safety and Monitoring Board (DSMB) is required when Phase III clinical
trials are to be supported.  The members of the DSMB shall be approved by the
NIAID Scientific Coordinator.  Projected costs associated with the DSMB meetings
need to be included in the CFS CRC budget.


The following terms and conditions will be incorporated into the award statement
and provided to the Principal Investigator as well as the institutional official
at the time of award.

These special Terms of Award are in addition to, and not in lieu of, otherwise
applicable OMB administrative guidelines, HHS Grant Administration Regulations
at 45 CFR part 74 and 92, and other HHS, PHS, and NIH Grant Administration policy

The administrative and funding instrument used for this program is the
multiproject cooperative agreement (U19), an "assistance"  mechanism (rather than
an "acquisition" mechanism), in which substantial NIH scientific and/or
programmatic involvement with the awardee is anticipated  during the performance
of the activity.  Under the cooperative agreement, the NIH purpose is to support
and/or stimulate the recipient's activity by involvement in and otherwise working
jointly with the award recipient in a partner role, but it is not to assume
direction, prime responsibility, or a dominant role in the activity.  Consistent
with this concept, the dominant role and prime responsibility for the activity
resides with the awardees for the project as a whole, although specific tasks and
activities in carrying out the research will be shared among the awardees and the
NIAID Scientific Coordinator.

A.  Awardee Rights and Responsibilities

Awardees will have primary responsibility for defining the research objectives,
approaches and details of the projects within the guidelines of the RFA and for
performing the scientific activity. Specifically, awardees have primary
responsibility as described below.

Awardees will retain custody of and have primary rights to data developed under
this award, subject to Government rights of access consistent with current DHHS,
PHS and NIH policies.

The CRC Director (the Principal Investigator for the CRC) shall specify criteria
for patient selection, but at a minimum all CRC CFS patients enrolled must meet
inclusion and exclusion criteria comparable to those specified by CDC and NIH so
that studies at different CRCs can be compared (Fukuda KF, Straus SF, Hickie I,
et al., Ann Intern Med. 1994; 121:953-959).

The CRC Director will have ultimate responsibility for the coordination of
efforts within the CRC and ensuring that the results obtained are analyzed
appropriately and published in a timely manner.  However, it will be the
responsibility of each CRC Project Leader (the Principal Investigator for an
individual research project within the CRC) to plan and conduct the research
stipulated in the project proposal.  NIAID may periodically review and generate
internal reports from data and progress reports developed under this cooperative
agreement.  The data obtained will, however, be the property of the awardee.

The multi-disciplinary and cooperative nature of the CFS CRCs creates an
extraordinary opportunity for information exchange and scientific advancement in
high quality CFS research.  It is expected that awardees will take advantage of
this opportunity by participating in both formal events established expressly for
this purpose and informal investigator-initiated dialogues.

B.  NIAID Staff Responsibilities

NIAID staff assistance will be provided by a Program Officer who will serve as
NIAID's Scientific Coordinator.  The NIAID Scientific Coordinator will have
substantial scientific/programmatic involvement during the conduct of this
activity through technical assistance, advice and coordination above and beyond
normal program stewardship for grants, as described below.

The NIAID Scientific Coordinator will be the Program Officer designated to
administer the CFS CRC program, currently in the DMID.  Release of set-aside
funds for pilot studies will require approval of the NIAID Scientific
Coordinator.  During the award period, the NIAID Scientific Coordinator will work
CRC.  It is anticipated that decisions in all activities outlined within this RFA
will be reached by consensus of the investigators and the NIAID Scientific

NIAID will facilitate research at CFS CRCs through the following:

o  assistance in overall research planning, data analysis and reporting;

o  facilitation of information exchange between CFS CRCs and other CFS grantees
and investigators;

o  reduction of duplication of efforts by CFS CRCs and other NIAID awardees;

o  assistance in development of standardization procedures applicable to current
and future CFS CRCs and in other grantees with regard to case definition,
laboratory procedures, selection of reagents, etc.;

o  facilitation of access to new research reagents and technologies;

o  assistance in review and approval of pilot studies;

o  identification of experts and other important resources not otherwise
available to the CFS CRCs;

o  assistance in locating potential replacements for key personnel vacancies
including Principal Investigators, Project Leaders and Co-Investigators.

o  membership on the External Advisory Board

C.  Collaborative Responsibilities

The CRC Directors, Project Leaders, and NIAID Scientific Coordinator will
communicate regularly by teleconference or at CFS related conferences, to review
progress, plan and design research activities, and establish CFS CRC priorities.

The CFC External Advisory Board will be established by the CRC Director.  The
NIAID Scientific Coordinator will be a member of that Board.

A Data Safety and Monitoring Board (DSMB) is required when Phase III clinical
trials are to be supported.  The members of the DSMB shall be selected by the
awardee and approved by the NIAID Scientific Coordinator.

In addition, each year, NIAID staff will coordinate one workshop at the NIH in
Bethesda, Maryland (or at a site designated by NIAID).  This workshop will
provide a forum for CRC and other CFS research grant awardees to share research
advances; to discuss CFS research needs and opportunities; and to develop
collaborations.  Funds for travel to these meetings must be included in the

D.  Arbitration

Any disagreement that may arise on scientific or programmatic matters (within the
scope of the award) between award recipients and the NIAID may be brought to
arbitration.  An arbitration panel will be composed of three members -- one
selected by the individual awardee in the event of an individual disagreement,
a second member selected by the NIAID, and the third member with expertise in the
relevant area and selected by the two prior members will be formed to review any
scientific or programmatic issue that is significantly restricting progress. 
While the decisions of the Arbitration Panel are binding, these special
arbitration procedures will in no way affect the awardee's right to appeal an 
adverse action in accordance with PHS regulations at 42 CFR Part 50, subpart D,
and HHS regulations at 45 CFR Part 16.


It is the policy of the NIH that women and members of minority groups and their
subpopulations must be included in all NIH supported biomedical and behavioral
research projects involving human subjects, unless a clear and compelling
rationale and justification are provided that inclusion is inappropriate with
respect to the health of the subjects of the purpose of the research.  This
policy results from the NIH Revitalization Act of 1993 (Section 492B of Public
Law 103-43).

All investigators proposing research involving human subjects should read the
"NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical
Research", which have been published in the Federal Register of March 28, 1994
(FR 59 14508-14513) and the NIH Guide for Grants and Contracts, Vol. 23, No. 11,
March 18, 1994.


It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subjects research, conducted or supported by the
NIH, unless there are scientific and ethical reasons not to include them.  This
policy applies to all initial (Type 1) applications  submitted for receipt dates
after October 1, 1998.

All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines on the Inclusion of Children as Participants in
Research Involving Human Subjects" that was published in the NIH Guide for Grants
and Contracts, March 6, 1998, and is available at the following URL address:


Prospective applicants are asked to submit, by June 15, 1998, a letter of intent
that includes a descriptive title of the overall proposed research, the name,
address and telephone number of the Principal Investigator, and the number and
title of this RFA.  Although the letter of intent is not required, is not
binding, does not commit the sender to submit an application, and does not enter
into the review of subsequent applications, the information that it contains
allows NIAID staff to estimate the potential review workload and to avoid
conflict of interest in the review.  The letter of intent is to be sent to Dr.
Madelon Halula at the address listed under INQUIRIES.


Applicants for U19 cooperative agreements must follow special application
guidelines in the NIAID Brochure entitled INSTRUCTIONS FOR APPLICATIONS FOR
MULTI-PROJECT AWARDS (September 1997); this brochure is available via the WWW 
at: http://www.niaid.nih.gov/ncn/grants/multibron.htm

Minimum Requirements for Application

Investigators are urged to contact NIAID staff early in the development of the
application.  Particular attention should be given to the following areas when
responding to the application instructions found in the brochure:

o  In describing the clinical and laboratory facilities available to the CRC,
specific information should be included on the institution's present CFS patient
load and projections for patients' willingness to participate in clinical
investigations.  A detailed account of case and control ascertainment procedures
must be provided along with the inclusion and exclusion criteria to be used for

o  A minimum of three projects must be proposed.  The detailed description of
each research project should demonstrate that it contributes to the attainment
of the CRC's overall objectives.  Preliminary results and evidence of feasibility
should be provided if available.

o  Previously funded CRCs must submit a comprehensive progress report and
carefully justify any plans for expansion.

o  The goal should be to mirror the CFS population with regard to gender in
studies of CFS.  Applications are urged to give added attention where feasible
and appropriate to the inclusion of minorities in study populations.  If
minorities are not included in the study population, a clear rationale for their
exclusion must be provided.

o  In addressing the Organization and Administration Structure of the CRC, the
mutually reinforcing inter-relationships among the members of the CFS CRC and the
contribution of each to fulfillment of CFS CRC objectives should be clearly
described.  This section must include an organizational chart showing the name,
the organization and the scientific discipline of the Program Director, the
Project Leaders (principal investigators of individual research projects), and
other key personnel for the projects.

o  The application must include a signed letter of agreement from each
collaborator and/or consultant to the program indicating:  (1) willingness to
participate in the program; and (2) the exact nature of the participation.

o  Plans to convene a CFS CRC External Advisory Board of experts in the field
should be described.  The Board will provide scientific advice to the CRC
Director and Project Leaders.  The Board will be constituted after award and
should not be named in the application.


A written commitment by the sponsoring institution which explicitly defines the
institution's willingness and preparedness to commit resources to ensure
development, function and maintenance of the proposed CFS CRC must be included
in the application.  This letter should be co-signed by the relevant departmental
chairperson(s) and dean of the institution.

In addition to support for personnel, supplies, travel to an annual CFS CRC
workshop for the CRC Director and Project Leaders, and for the External Advisory
Board and other necessary costs justified in the application for conducting CRC
research projects, award funds may be utilized to support the following research-
related activities:

funds for administration, equipment, supplies and services to expand and/or
maintain clinical, laboratory, biostatistical and data management facilities
which are shared by research staff from at least two CRC research projects. 
Costs associated with patient and control recruitment, enrollment, follow-up and
data entry would be appropriate for a core budget.  Any research-related cost for
patient and control subject enrollment that is not eligible for third-party
payment should be included in the budget as PATIENT CARE COSTS.

The amounts requested for Core Support should be well justified and in keeping
with the overall complexity and size of the budget.  In any case, such costs may
not duplicate or replace costs included in the institution's indirect cost base. 
Since the program cannot provide funds for new construction, adequate physical
facilities must be available to meet the primary needs of the CRC.  Please read
pages 17-18 of the NIAID booklet Multiproject Grants.

o  BIOSTATISTICAL SUPPORT:  The budget should include adequate biostatistical
support to ensure sound study design, data collection and data analysis

o  OTHER BUDGETABLE ITEMS:  Budget requests may also include limited investigator
travel and costs for publication.

o  DEVELOPMENTAL FUND FOR PILOT STUDIES:  Applicants may request that $40,000 in
direct costs be made available annually in a Developmental Fund for pilot
studies.  This Developmental Fund would be set aside and restricted solely to
cover salaries and other research costs for small pilot studies to follow-up on
new observations and novel hypotheses.  It is envisioned that availability of
funds for pilot studies would increase flexibility and responsiveness to
important new scientific observations and medical reports.

Pilot studies need not be restricted to the awardee institution.  IT IS

The direct costs may not exceed $40,000 for any single pilot study.  The duration
of support for each study typically would be 1 year, but may be up to 3 years,
unless the study is independently funded through a traditional research grant
(R01) award prior to the end of the 3-year period.  In these instances, the pilot
study must be terminated, and unexpended funds must be returned to the
Developmental Fund.  Funds reserved for pilot projects may not be rebudgeted into
other budget categories except in unusual circumstances and following approval
from the Grants Management Specialist and the Scientific Coordinator.  The CRC
must maintain detailed records of disbursements and expenditures from the
Developmental Fund.

Procedures for soliciting and selection of pilot studies should be described if
developmental funds are requested.  It is anticipated that pilot studies and
their budgets recommended by the CFS CRC Director will be reviewed and selected
by a local review committee.  Studies involving Human Subjects will require prior
approval by the Institutional Review Board like all other NIH supported projects. 
Budgets for pilot projects submitted by the CRC Director must be countersigned
by the institutional financial officer.  Finally, release of funds set aside for
this purpose will require approval of the NIAID Scientific Coordinator.

DESCRIBED IN THE CRC APPLICATION.  Only the solicitation process and selection
method (institutional review process) and review criteria to be used need be
described.  Examples of criteria are scientific merit of the proposal, medical
relevance and need for data to advance the research objectives of the CRC.

The $40,000 annual direct costs should be entered in the OTHER category in the
Consolidated Budget (see pages 15 and 21 in NIAIDþs INSTRUCTIONS FOR APPLICATIONS

Applications are to be submitted on the research grant application form PHS 398
(rev. 5/95).  Application kits are available at most institutional offices of
sponsored research and may be obtained from the Division of Extramural Outreach
and Information Resources, National Institutes of Health, 6701 Rockledge Drive,
MSC 7910, Bethesda, MD 20892-7910, telephone (301) 710-0267, email:

For purposes of identification and processing, item 2 on the face page of the
application must be marked "YES" and the RFA number "AI-98-008" and the words
"Chronic Fatigue Syndrome Cooperative Research Centers" must be typed in.

Applications must be received by October 14, 1998.  Applications that are not
received as a single package on the receipt date or that do not conform to the
instructions contained in PHS 398 (rev. 5/95) Application Kit (as modified in,
MULTI-PROJECT AWARDS"), will be judged non-responsive and will be returned to the
applicant.  The RFA label available in the application form PHS 398 must be
affixed to the bottom of the face page.  Failure to use this label could result
in delayed processing of the application such that it may not reach the review
committee in time for review.

Applicants from institutions that have a General Clinical Research Center (GCRC)
funded by the NIH National Center for Research Resources may wish to identify the
GCRC as a resource for conducting the proposed research.  If so, a letter of
agreement from either the GCRC program director or principal investigator could
be included with the application.

It is highly recommended that the appropriate NIAID program contact be consulted
before submitting the letter of intent and during the early stages of preparation
of the application.  (See program contact under INQUIRIES).

Submit a signed, typewritten original of the application, including the
checklist, and three signed, exact, single-sided photocopies, in one package to:

6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD  20892-7710
BETHESDA, MD  20817 (for express/courier service)

At the time of submission, two additional exact copies of the grant application
and all five sets of any appendix material must be sent to Dr. Madelon Halula at
the address listed under INQUIRIES.

Concurrent submission of an R01 and a Component Project of a Multi-project
Application:  Current NIH policy permits a component research project of a multi-
project grant application to be concurrently submitted as a traditional
individual research project (R01) application.  If, following review, both the
multi-project application and the R01 application are found to be in the fundable
range, the investigator must relinquish the R01 and will not have the option to
withdraw from the multi-project grant.  This is an NIH policy intended to
preserve the scientific integrity of a multi-project grant, which may be
seriously compromised if a strong component project(s) is removed from the

Investigators wishing to participate in a multi-project grant must be aware of
this policy before making a commitment to the Principal Investigator and awarding


Applicants for U19 cooperative agreements must follow special application
guidelines in the NIAID Brochure entitled INSTRUCTIONS FOR APPLICATIONS FOR
MULTI-PROJECT AWARDS (September 1997); this brochure is available from NIAID
listed under INQUIRIES via the WWW at: 

This brochure presents specific instructions for sections of the PHS 398 (rev.
5/95) application form that should be completed differently than usual.


Review Procedures

Upon receipt, applications will be reviewed for completeness by the NIH Center
for Scientific Review and for responsiveness by NIAID staff.  Incomplete and/or
non-responsive applications will be returned to the applicant without further

Applications that are complete and responsive to the RFA will be evaluated for
scientific and technical merit by an appropriate peer review group convened by
the NIAID in accordance with the review criteria stated below.  As part of the
initial merit review, a process may be used by the initial review group in which
applications will be determined to be competitive or non-competitive based on
their scientific merit relative to other applications received in response to the
RFA.  Applications judged to be competitive will be discussed and be assigned a
priority score.  Applications determined to be non-competitive will be withdrawn
from further consideration and the Principal Investigator and the official
signing for the applicant organization will be notified.  The second level of
review will be provided by the National Advisory Allergy and Infectious Diseases

Review Criteria

The general criteria for U19 multiproject cooperative agreement applications are
AWARDS.  Additional review criteria specific to this RFA are:

Appropriateness and adequacy of clinical facility with accessible patient
populations that are appropriate for answering CFS research questions and are
available for follow-up.

Appropriateness and adequacy of characterization of cases and controls, of
recruitment and retention procedures, and of data and specimen collection and
analysis methods.

Evidence that the CRC Director and project directors have sufficient experience
and expertise to make a significant contribution to the establishment of
standardized procedures for studying CFS.


Funding decisions will be made on the basis of scientific and technical merit as
determined by peer review, program balance, and the availability of funds.


Written and telephone inquiries concerning this RFA are encouraged.  The
opportunity to clarify any issues or questions from potential applicants is

AWARDS" as well as inquiries regarding programmatic (research scope and
eligibility) issues, may be directed to:

Leigh A. Sawyer, DVM, MPH
Division of Microbiology and Infectious Disease
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 3A15
Bethesda, MD  20892-7630
Telephone:  (301) 496-7453
FAX:  (301) 402-0659
Email:  ls98a@nih.gov

Direct inquiries regarding preparation of the application and review issues,
address the letter of intent to, and mail two copies of the application and all
five sets of appendices to:

Dr. Madelon Halula
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 4C16
Bethesda, MD  20892-7610
Telephone:  (301) 402-2636
FAX:  (301) 402-2638
Email:  mh30x@nih.gov

Direct inquiries regarding fiscal matters to:

Todd C. Ball
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 4B35
Bethesda, MD  20892-7610
Telephone:  (301) 496-7075
Email:  tb22j@nih.gov


Letter of Intent Receipt Date:   June 15, 1998
Application Receipt Date:        October 14, 1998
Scientific Review Date:          February 1999
Advisory Council Date:           May 24, 1999
Earliest Date of Award:          August 1, 1999


This program is supported under authorization of the Public Health Service Act,
Sec. 301 (c), Public Law 78-410, as amended.  The Catalogue of Federal Domestic
Assistance Citation is Sec. 93.856, Microbiology and Infectious Diseases
Research.  Awards will be administered under PHS grants policies and Federal
Regulations 42 CFR Part 52 and 45 CFR Part 74.  This program is not subject to
the intergovernmental review requirements of Executive Order 12372 or Health
Systems review.

The PHS strongly encourages all grant and contract recipients to provide a smoke-
free workplace and promote the non-use of all tobacco products.  In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care or early childhood development
services are provided to children.  This is consistent with the PHS mission to
protect and advance the physical and mental health of the American people.

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.